SEBI Says 'All Clear'—Fredun Gets Clean Chit, No Cash Cost

Regulatory Update SEBI has issued an adjudication order on June 30, 2025, against Fredun Pharmaceuticals Ltd following a multi-year probe for alleged violations of listing regulations. Surprisingly, SEBI has decided not to impose any monetary fine in consideration of the retrospective defaults and absence of damage to stakeholders.

Key Highlights

SEBI probe included deficiency in compliance in FY 2017 and FY 2022

Fees were charged for failure to prepare Ind AS financials, hiring non-peer-review auditors, and incorrect corporate governance certifications

The firm was also accused of quorum violations in audit committee meetings and non-disclosure of compliance certificates in annual reports

Company's Defense

Fredun Pharma argued that the deficiencies resulted from interpretative errors and did not cause material misstatements

The firm has since employed peer-reviewed auditors and strengthened compliance protocols

SEBI acknowledged previous fines imposed by stock exchanges and endorsed the remedial actions of the company

Strategic Outlook

The court ruling allows Fredun Pharma to conduct its business without making financial losses

The firm will most probably strengthen its governance framework and increase board-level oversight

Investors will be able to read the resolution as an indication of regulatory maturity and operating resilience

Market Environment

Fredun Pharma share price is stable, with a market capitalisation of approximately Rs 381 crore

The company recently achieved a net profit of Rs 21 crore and maintains a low debt equity ratio.

Sources: SEBI, Economic Times, Rediff MoneyWiz, CaseMine, Value Research Online